- Home
- CHEK vs APVO Comparison
CHEK vs APVO Comparison
Compare CHEK & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- APVO
- Stock Information
- Founded
- CHEK 2004
- APVO 2016
- Country
- CHEK Israel
- APVO United States
- Employees
- CHEK 85
- APVO N/A
- Industry
- CHEK Medical Electronics
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- APVO Health Care
- Exchange
- CHEK Nasdaq
- APVO Nasdaq
- Market Cap
- CHEK 4.8M
- APVO 4.1M
- IPO Year
- CHEK 2015
- APVO N/A
- Fundamental
- Price
- CHEK $0.80
- APVO $4.95
- Analyst Decision
- CHEK
- APVO Strong Buy
- Analyst Count
- CHEK 0
- APVO 1
- Target Price
- CHEK N/A
- APVO $5,920.00
- AVG Volume (30 Days)
- CHEK 125.3K
- APVO 393.8K
- Earning Date
- CHEK 06-17-2025
- APVO 05-14-2025
- Dividend Yield
- CHEK N/A
- APVO N/A
- EPS Growth
- CHEK N/A
- APVO N/A
- EPS
- CHEK N/A
- APVO N/A
- Revenue
- CHEK N/A
- APVO N/A
- Revenue This Year
- CHEK N/A
- APVO N/A
- Revenue Next Year
- CHEK N/A
- APVO N/A
- P/E Ratio
- CHEK N/A
- APVO N/A
- Revenue Growth
- CHEK N/A
- APVO N/A
- 52 Week Low
- CHEK $0.56
- APVO $4.30
- 52 Week High
- CHEK $3.04
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- CHEK 46.52
- APVO 28.32
- Support Level
- CHEK $0.78
- APVO $4.30
- Resistance Level
- CHEK $0.86
- APVO $5.18
- Average True Range (ATR)
- CHEK 0.04
- APVO 1.22
- MACD
- CHEK -0.01
- APVO 0.72
- Stochastic Oscillator
- CHEK 15.73
- APVO 6.47
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.